SCHEMBL15038459

SCHEMBL15038459

O=C1NC(=O)N(Cc2ccc(Cl)cc2)CCN1Cc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.54
ERCC4 Q92889 1/20 0.54
DDB1 Q16531 1/20 0.51
CRBN Q96SW2 1/20 0.51
DRD3 P35462 1/20 0.49
KCNH2 Q12809 1/20 0.49
GAA P10253 1/20 0.49
ALDH1A1 P00352 4/20 0.49
POLB P06746 1/20 0.49
P2RX7 Q99572 2/20 0.48
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 2/20 0.46
SIGMAR1 Q99720 1/20 0.46
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18835005 0.88 ERCC1 (0.48) ERCC1ERCC4DDB1CRBNDRD3
SCHEMBL4749191 0.82 ALDH1A1 (0.71) ERCC1ERCC4DRD3KCNH2ALDH1A1
SCHEMBL9164640 0.81 EPHX2 (0.49) ERCC1ERCC4DDB1CRBNDRD3
SCHEMBL4786883 0.78 SMN1; SMN2 (0.73) ERCC1ERCC4DRD3KCNH2ALDH1A1
SCHEMBL15015764 0.78 MEN1 (0.42) ERCC1ERCC4ALDH1A1MAPTKDM4E
SCHEMBL18835681 0.77 ERCC1 (0.59) ERCC1ERCC4DRD3KCNH2ALDH1A1
SCHEMBL4692001 0.74 MEN1 (0.47) ERCC1ERCC4DRD3KCNH2ALDH1A1
SCHEMBL9514131 0.73 ALDH1A1 (0.60) ERCC1ERCC4DRD3KCNH2ALDH1A1
SCHEMBL10399987 0.73 L3MBTL1 (0.67) ERCC1ERCC4KCNH2GAAALDH1A1
SCHEMBL4786748 0.73 HTR2C (0.49) ERCC1ERCC4KCNH2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604260-B1 NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SHIONOGI & CO (JP) 2017-05-10 EP disclosed
US-9212130-B2 Heterocyclic derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2015-12-15 US disclosed
US-9212130-B2 Heterocyclic derivative and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2015-12-15 US disclosed
US-20130225596-A1 NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) SHIONOGI & CO., LTD. (JP) 2013-08-29 US disclosed
EP-2604260-A1 NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Shionogi&Co., Ltd. (JP) 2013-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225596-A1 NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) P2RX3, P2RX6, P2RX2 ERCC1 4304/4885ERCC4 4162/4885DDB1 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.